Pharvaris N.V. - Ordinary Shares, Euro 0.12 par value per share (PHVS)

Historical Holders from Q1 2021 to Q3 2025

Type / Class
Equity / Ordinary Shares, Euro 0.12 par value per share
Symbol
PHVS on Nasdaq
Shares outstanding
62,254,300
Price per share
$24.95
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
57,844,608
Total reported value
$1,443,142,875
% of total 13F portfolios
0.02%
Share change
+9,379,765
Value change
+$236,461,386
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
83
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Pharvaris N.V. - Ordinary Shares, Euro 0.12 par value per share (PHVS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Venrock Healthcare Capital Partners III, L.P. 3.8% $46,767,641 2,047,620 Venrock Healthcare Capital Partners III, L.P. 30 Jun 2025
Bain Capital Life Sciences Fund, L.P. 3% $46,597,344 1,867,629 Bain Capital Life Sciences Fund, L.P. 30 Sep 2025
As of 30 Sep 2025, Pharvaris N.V. - Ordinary Shares, Euro 0.12 par value per share (PHVS) has 83 institutional shareholders filing 13F forms. They hold 57,844,608 shares. of 62,254,300 outstanding shares (93%) .

Top 25 institutional shareholders own 86% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
GENERAL ATLANTIC, L.P. 13% 8,031,252 +6.6% 6% $200,379,737
FMR LLC 10% 6,399,158 +18% 0.01% $159,658,992
Foresite Capital Management IV, LLC 7.7% 4,778,581 +8.3% 65% $119,225,596
venBio Partners LLC 7.5% 4,639,304 +8.2% 66% $115,750,635
VIKING GLOBAL INVESTORS LP 5.9% 3,653,310 0% 0.24% $91,150,085
EQT Fund Management S.a r.l. 5.5% 3,424,609 0% 4.6% $85,443,995
Bain Capital Life Sciences Investors, LLC 5.1% 3,181,275 -3.7% 5.3% $79,372,811
DEERFIELD MANAGEMENT COMPANY, L.P. 3.9% 2,442,464 +21% 0.93% $60,939,477
Commodore Capital LP 3.9% 2,418,476 +27% 2.9% $60,340,976
Paradigm Biocapital Advisors LP 2.9% 1,835,494 +73% 1.4% $45,795,575
NOVO HOLDINGS A/S 2.8% 1,750,000 +1.4% 2.8% $43,662,500
WELLINGTON MANAGEMENT GROUP LLP 2.8% 1,734,743 0.01% $43,281,838
Cormorant Asset Management, LP 2.2% 1,363,200 -6.3% 2.3% $34,011,840
Saturn V Capital Management LP 1.4% 886,332 4.8% $22,113,983
PRICE T ROWE ASSOCIATES INC /MD/ 1.3% 816,808 +6.5% 0% $20,380,000
5AM Venture Management, LLC 1.3% 797,600 0% 7.3% $19,900,120
Sofinnova Investments, Inc. 1.2% 739,876 +26% 1.1% $18,459,906
Octagon Capital Advisors LP 1.2% 722,595 +7.4% 2.8% $18,028,745
Kynam Capital Management, LP 1.1% 675,000 1.3% $16,841,250
VR ADVISER, LLC 1.1% 674,599 -67% 0.95% $16,831,245
Soleus Capital Management, L.P. 1% 647,052 -12% 0.86% $16,143,947
Balyasny Asset Management L.P. 1% 625,758 0.03% $15,612,662
Rock Springs Capital Management LP 1% 623,402 0% 0.91% $15,553,880
Point72 Asset Management, L.P. 0.83% 519,381 +1281% 0.03% $12,958,557
BlackRock, Inc. 0.67% 414,417 +106% 0% $10,339,704

Institutional Holders of Pharvaris N.V. - Ordinary Shares, Euro 0.12 par value per share (PHVS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q3 57,844,608 $1,443,142,875 +$236,461,386 2,495% 83
2025 Q2 45,040,180 $792,712,813 +$1,806,097 1,760% 60
2025 Q1 44,939,067 $705,543,867 +$4,132,734 1,570% 52
2024 Q4 44,644,168 $855,824,077 -$7,190,147 1,917% 54
2024 Q3 45,045,428 $834,243,398 +$34,119,569 1,852% 51
2024 Q2 43,008,763 $808,565,649 +$10,680,397 1,880% 36
2024 Q1 42,425,740 $980,459,437 +$36,576,974 2,311% 35
2023 Q4 40,745,703 $1,142,917,292 +$328,263,856 2,805% 36
2023 Q3 29,067,102 $606,630,419 +$4,468,801 2,087% 21
2023 Q2 28,913,752 $441,577,880 +$109,618,998 1,514% 21
2023 Q1 21,781,494 $173,888,454 +$3,756,314 805.5% 21
2022 Q4 21,301,855 $239,644,411 -$1,830,562 1,125% 25
2022 Q3 22,314,954 $173,600,000 -$317,119 767.02% 21
2022 Q2 22,353,338 $494,009,000 +$14,912,668 2,210% 20
2022 Q1 21,685,311 $397,089,000 +$837,870 1,814.24% 21
2021 Q4 21,647,018 $321,068,000 -$1,695,275 1,439.01% 22
2021 Q3 21,631,638 $380,302,000 -$6,827,491 1,772.99% 25
2021 Q2 21,995,815 $406,288,000 -$1,442,842 1,862.35% 28
2021 Q1 22,025,122 $616,507,000 +$616,506,894 2,799.12% 33